Background: Previous studies revealed that cancer-associated differentially expressed genes (DEGs) in an independent cancer type are rarely related to the tumorigenesis and metastasis, while the common DEGs across multiple types of cancer may be proved as potential oncogenes or tumor suppressors. Although tumor-infiltrating immune cells have been reported to be associated with prognosis in multiple types of cancer, the hub genes regulating immune cells function in different cancer types remain unclear. Methods: To screen for the hub genes regulating immune infiltrating level across multiple tumors microenvironment, the raw data containing RNA sequencing and clinical information from TCGA database and immune scores from ESTIMATE website across 25 cancer types were obtained. Results: Based on the immune scores, all cases were categorized into high-score and low-score groups. Kaplan–Meier survival analysis demonstrated that a strong correlation between immune infiltrating level and survival prognosis was found in six cancer types. The functional enrichment analysis of common DEGs revealed that infection and immune response are the most prominent biological characteristics. Subsequently, the twelve common DEGs with prognostic value were identified as candidate hub genes and were adopted to construct the PPI network. Because of highly interconnected with other hub genes, protein tyrosine phosphatase non-receptor type 6 (PTPN6) was selected as the real hub gene across the six immune-specific tumors. Finally, a significant correlation between PTPN6 and immune infiltrating level, and immune marker sets of various immune cells were observed. Conclusion: PTPN6 may play a vital role in regulating immune response for tumor development, due to its significant correlation with tumor-infiltrating immune cells in multiple cancers.
Background Although serum tumour markers (STMs), clinicopathological characteristics and the status of KRAS and MMR play an important role in optimizing the treatment and improving the prognosis of colorectal cancer, their interrelationships remain largely unknown. Methods A retrospective analysis of 2279 patients who underwent KRAS or MMR status testing and STM measurements prior to treatment over the past four years was conducted. Univariate and multivariate logistic regression were performed to identify independent predictive factors of KRAS and MMR status. The area under receiver operating characteristic (ROC) curve (AUC) was used to evaluate the predictive value of individual and combined factors. Results Of the 784 patients tested for KRAS and 2279 patients tested for MMR status, KRAS mutations and dMMR were identified in 276 patients (35.20%) and 177 patients (7.77%), respectively. Logistic regression analysis demonstrated that right colon, well and moderate differentiation and negative CA19-9 were independent predictors for KRAS mutations. The ROC curve yielded an AUC of 0.609 for the combination of the three factors. Age < 65 was an independent predictive factor for dMMR, along with tumour size > 4.6 cm, right colon, poor differentiation, harvested lymph nodes ≥ 22, no lymph node metastasis, no perineural invasion, negative CEA and positive CA72-4. When the nine criteria were used together, the AUC was 0.849. Conclusion Both STMs and clinicopathological characteristics were found to be significantly associated with the status of KRAS and MMR. The combination of these two factors possessed a strong predictive power for targeted genes among CRC patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.